|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008574,
umls-concept:C0009148,
umls-concept:C0010068,
umls-concept:C0032521,
umls-concept:C0038257,
umls-concept:C0087111,
umls-concept:C0205171,
umls-concept:C0205225,
umls-concept:C0205314,
umls-concept:C0333186,
umls-concept:C0679622,
umls-concept:C1274040,
umls-concept:C2603343
|
|
pubmed:issue |
16
|
|
pubmed:dateCreated |
2008-4-18
|
|
pubmed:abstractText |
The aim was to compare safety and effectiveness of the CoStar drug-eluting stent (DES) (Conor MedSystems, Menlo Park, California) with those of the Taxus DES (Boston Scientific, Maple Grove, Minnesota) in de novo single- and multivessel percutaneous coronary intervention (PCI).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1558-3597
|
|
pubmed:author |
pubmed-author:BatchelorWayne BWB,
pubmed-author:BuchbinderMauriceM,
pubmed-author:COSTAR II Investigators Group,
pubmed-author:DuboisChristophe LCL,
pubmed-author:FitzgeraldPeter JPJ,
pubmed-author:GammonRogerR,
pubmed-author:GargJyotsnaJ,
pubmed-author:HasselbladVicV,
pubmed-author:HermillerJames BJBJr,
pubmed-author:KereiakesDean JDJ,
pubmed-author:KrucoffMitchell WMW,
pubmed-author:LanskyAlexandra JAJ,
pubmed-author:MehranRoxanaR,
pubmed-author:O'ShaughnessyCharles DCD,
pubmed-author:PetersenJohn LJL,
pubmed-author:SchoferJoachimJ,
pubmed-author:SimontonCharles ACA3rd,
pubmed-author:TurcoMark AMA,
pubmed-author:VerheyeStefanS,
pubmed-author:WijnsWilliamW
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
22
|
|
pubmed:volume |
51
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1543-52
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18420096-Absorbable Implants,
pubmed-meshheading:18420096-Angioplasty, Balloon, Coronary,
pubmed-meshheading:18420096-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:18420096-Chromium Alloys,
pubmed-meshheading:18420096-Coronary Angiography,
pubmed-meshheading:18420096-Coronary Artery Disease,
pubmed-meshheading:18420096-Coronary Restenosis,
pubmed-meshheading:18420096-Diabetes Mellitus,
pubmed-meshheading:18420096-Female,
pubmed-meshheading:18420096-Humans,
pubmed-meshheading:18420096-Male,
pubmed-meshheading:18420096-Middle Aged,
pubmed-meshheading:18420096-Paclitaxel,
pubmed-meshheading:18420096-Platelet Aggregation Inhibitors,
pubmed-meshheading:18420096-Polymers,
pubmed-meshheading:18420096-Risk,
pubmed-meshheading:18420096-Thromboembolism,
pubmed-meshheading:18420096-Ticlopidine,
pubmed-meshheading:18420096-Time Factors
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
|
|
pubmed:affiliation |
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA. kruco001@mc.duke.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
